Brief: Elicio Therapeutics Announces Clinical Supply Agreement With Regeneron To Evaluate ELI-002 In Combination With Libtayo In Kras-Driven Tumors
16/05/2022 13:12
May 16 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT
WITH
REGENERON TO EVALUATE ELI-002 IN COMBINATION WITH LIBTAYO®
(CEMIPLIMAB) IN KRAS-DRIVEN TUMORS
Source text for Eikon: ID:nGNXb9CTDB
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)